Ensysce Biosciences (ENSC) EBT Margin (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly EBT Margin of 759.97% for Q3 2025, down 77871.0% year-over-year from N/an in Q3 2024, and down 494.33% quarter-over-quarter from 127.87% in Q2 2025.
Ensysce Biosciences (ENSC) EBT Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported EBT Margin for 6 consecutive years, with 759.97% the latest figure, recorded in Q3 2025.
- In Q3 2025, EBT Margin fell 77871.0% year-over-year to 759.97%; the TTM figure through Sep 2025 stood at 246.25% (down 7448.0% YoY), while the FY2024 annual figure was 153.78%, up 40296.0% from the prior year.
- EBT Margin retreated to 759.97% in Q3 2025 per ENSC's latest filing, from 127.87% in the prior quarter.
- Across five years, EBT Margin topped out at 18.74% in Q3 2024 and bottomed at 12176.69% in Q2 2021.
- Historically, EBT Margin has averaged 1418.87% across 5 years, with a median of 623.58% in 2023.
- Annual changes were most pronounced in 2021 — EBT Margin slumped 1217326 bps — and 2022, when it jumped 875371 bps.
- Ensysce Biosciences' EBT Margin stood at 128.68% in 2021, then slumped by 242 bps to 439.74% in 2022, then slumped by 40 bps to 613.8% in 2023, then soared by 55 bps to 274.55% in 2024, then sank by 177 bps to 759.97% in 2025.
- Business Quant data shows ENSC's EBT Margin at 759.97% in Q3 2025, 127.87% in Q2 2025, and 149.37% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -759.97% |
| Jun 30, 2025 | -127.87% |
| Mar 31, 2025 | -149.37% |
| Dec 31, 2024 | -274.55% |
| Sep 30, 2024 | 18.74% |
| Jun 30, 2024 | -1,090.78% |
| Mar 31, 2024 | -1,011.06% |
| Dec 31, 2023 | -613.80% |
| Sep 30, 2023 | -623.58% |
| Jun 30, 2023 | -467.70% |
| Mar 31, 2023 | -324.55% |
| Dec 31, 2022 | -439.74% |
| Sep 30, 2022 | -2,208.04% |
| Jun 30, 2022 | -3,422.98% |
| Mar 31, 2022 | -798.85% |
| Dec 31, 2021 | -128.68% |
| Sep 30, 2021 | -1,651.47% |
| Jun 30, 2021 | -12,176.69% |
| Mar 31, 2021 | -707.52% |
| Dec 31, 2020 | -322.05% |